Conditions: Huntington's Disease
Keywords: Neurodegenerative genetic disorder
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 17
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BN82451B versus placebo after oral administration twice daily (bid) for 28 days in patients with Huntington's Disease (HD).

Detailed description:

Arms:
arm 1: BN82451B capsule: Up to 3 dose levels (40, 60 or 80 mg) twice daily administered orally. arm 2: Placebo capsule: Up to 3 dose levels (40, 60 or 80 mg) twice daily administered orally.

Interventions: intervention 1: BN82451B intervention 2: Placebo
Intervention descriptions: intervention 1: BN82451B capsule intervention 2: Placebo capsule

Protocol document: